cmAngio® vs ZEUS System (Zio Watch)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 68/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

cmAngio®

by CureMetrix

ZEUS System (Zio Watch)

by iRhythm Technologies, Inc.

AI Verdict

Tool A, cmAngio®, focuses on leveraging AI to detect Breast Arterial Calcifications on mammograms for cardiovascular risk assessment, primarily within radiology and women's health. Tool B, the ZEUS System (Zio Watch), utilizes a wearable device and AI for continuous, long-term monitoring to detect and characterize cardiac arrhythmias like AFib. While both contribute to cardiovascular health insights through AI, they do so through distinct modalities and address different clinical questions, making them complementary rather than directly competitive.

Choose cmAngio® if…

Choose cmAngio® if you aim to leverage existing mammography data for proactive cardiovascular risk assessment in women. This AI software identifies Breast Arterial Calcifications (BAC) on mammograms, providing valuable insights into cardiovascular health without requiring additional procedures. It is ideal for integrating cardiovascular risk stratification into routine breast imaging workflows.

View cmAngio® →

Choose ZEUS System (Zio Watch) if…

Choose the ZEUS System (Zio Watch) if you require long-term, continuous cardiac monitoring to detect and characterize arrhythmias such as Atrial Fibrillation. This wearable device and AI-powered system provide actionable insights for physicians by continuously collecting ECG and PPG data for up to 14 days. It is best suited for patients needing direct and extended monitoring of their heart rhythm for diagnostic or management purposes.

View ZEUS System (Zio Watch) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	cmAngio®	ZEUS System (Zio Watch)
Pricing	Paid, out-of-pocket	Contact vendor
Deployment	Cloud-based, integrates with any DICOM-compliant viewer	Cloud-based system with a wearable device
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	cmAngio®	ZEUS System (Zio Watch)
Name	cmAngiou00ae	ZEUS System (Zio Watch)
Company	CureMetrix	iRhythm Technologies
Description	FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment.	FDA-cleared, AI-powered wearable for long-term continuous cardiac monitoring, specifically designed to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias, providing actionable insights for physicians.
Primary Function	AI-based detection of Breast Arterial Calcifications (BAC)	AI-powered algorithm (ZEUS System) for advanced arrhythmia detection and analysis
Key Feature 1	AI-based detection of Breast Arterial Calcifications (BAC)	Wearable biosensor (Zio Watch) for continuous ECG and PPG data collection
Key Feature 2	Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams	AI-powered algorithm (ZEUS System) for advanced arrhythmia detection and analysis

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and ZEUS System (Zio Watch).

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of cmAngiou00ae and the ZEUS System?

cmAngiou00ae is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. The ZEUS System (Zio Watch) is an FDA-cleared, AI-powered wearable for long-term continuous cardiac monitoring, specifically designed to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias.

How do these tools acquire patient data?

cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. The ZEUS System utilizes a wearable biosensor (Zio Watch) for continuous ECG and PPG data collection.

What types of patient populations or specialties are these tools primarily designed for?

cmAngiou00ae is relevant for women undergoing mammography, with applications in Cardiology, Obstetrics & Gynecology, and Radiology. The ZEUS System is designed for patients requiring long-term cardiac monitoring for arrhythmias, serving specialties such as Cardiology, Family Medicine, and Internal Medicine.

What kind of output or reports do these systems provide to physicians?

cmAngiou00ae provides visualization of BAC location on a scorecard and enables BAC identification and reporting. The ZEUS System delivers clinically actionable reports with advanced arrhythmia detection and analysis, including characterization of AFib burden, accessible via the ZioSuiteu00ae portal and provider mobile app.

Do these tools involve additional radiation or procedures for data collection?

cmAngiou00ae enables BAC identification and reporting without additional radiation or procedures, as it processes existing mammogram exams. The ZEUS System uses a wearable biosensor for continuous ECG and PPG data collection, which is a non-invasive external device.

What is the duration or type of monitoring offered by each tool?

cmAngiou00ae performs an analysis on individual mammogram exams. The ZEUS System provides long-term continuous monitoring for up to 14 days using its wearable biosensor.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring cmAngio® or ZEUS System (Zio Watch)

Backers

Who funded each tool's parent company.

cmAngio®

Keshif Ventures